Participants 173 277 4
elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies
Participants 452 516 3
elderly patients with advanced, low-grade non-Hodgkin's lymphoma
Participants 675 778 6
One hundred and fifty-five patients were randomized, 144 were evaluable for safety and 142 for response
